Advertisement
Screener

REVELATION BIOSCIENCES, INC. (REVB) Other Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

REVELATION BIOSCIENCES, INC. Other Research and Development Expense

REVELATION BIOSCIENCES, INC. (REVB) reported Other Research and Development Expense of $131.58 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-06

  • REVELATION BIOSCIENCES, INC. other research and development expense for the quarter ending 2026-06-30 was $131.58K, a 539.66% increase year-over-year.
  • REVELATION BIOSCIENCES, INC. other research and development expense for the quarter ending 2026-03-31 was $179.59K, a 660.55% increase year-over-year.
  • REVELATION BIOSCIENCES, INC. other research and development expense for the quarter ending 2025-12-31 was $99.46K, a 0.03% increase year-over-year.
  • REVELATION BIOSCIENCES, INC. other research and development expense for the quarter ending 2025-09-30 was $24.90K, a 10.91% increase year-over-year.
  • REVELATION BIOSCIENCES, INC. other research and development expense for fiscal 2025 was $168.54K, a 2.22% decline from fiscal 2024.
  • REVELATION BIOSCIENCES, INC. other research and development expense for fiscal 2024 was $172.37K, a 39.08% decline from fiscal 2023.
  • REVELATION BIOSCIENCES, INC. other research and development expense for fiscal 2023 was $282.95K.
Period endOther Research and Development Expense 3 monthOther Research and Development Expense 6 monthOther Research and Development Expense 9 monthOther Research and Development Expense 12 month
2026-06-30$131.58K
10-Q · filed 2026-08-06
$308.91K
10-Q · filed 2026-08-06
$410.62K
derived: sum of 3 quarters · filed 2026-08-06
$435.52K
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$179.59K
10-Q · filed 2026-05-07
$279.04K
derived: sum of 2 quarters · filed 2026-05-07
$303.94K
derived: sum of 3 quarters · filed 2026-05-07
$324.51K
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$99.46K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$124.35K
derived: sum of 2 quarters · filed 2026-02-26
$144.92K
derived: sum of 3 quarters · filed 2026-08-06
$168.54K
10-K · filed 2026-02-26
2025-09-30$24.90K
10-Q · filed 2025-11-06
$45.47K
derived: sum of 2 quarters · filed 2026-08-06
$69.08K
10-Q · filed 2025-11-06
$168.50K
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$20.57K
10-Q · filed 2026-08-06
$44.18K
10-Q · filed 2026-08-06
$143.61K
derived: sum of 3 quarters · filed 2026-08-06
$166.05K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$23.61K
10-Q · filed 2026-05-07
$123.04K
derived: sum of 2 quarters · filed 2026-05-07
$145.48K
derived: sum of 3 quarters · filed 2026-05-07
$257.66K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$99.42K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$121.87K
derived: sum of 2 quarters · filed 2026-02-26
$234.05K
derived: sum of 3 quarters · filed 2026-02-26
$172.37K
10-K · filed 2026-02-26
2024-09-30$22.45K
10-Q · filed 2025-11-06
$134.63K
derived: sum of 2 quarters · filed 2025-11-06
$72.95K
10-Q · filed 2025-11-06
2024-06-30$112.18K
10-Q · filed 2025-08-08
$201.19K
10-Q · filed 2025-08-08
2024-03-31$89.02K
10-Q · filed 2025-05-08
2023-12-31$282.95K
10-K · filed 2025-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
Onconetix, Inc. (ONCO)United States$0.004B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Sunshine Biopharma Inc. (SBFM)$0.003B
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Genprex, Inc. (GNPX)United States$0.003B-0.02
Silo Pharma, Inc. (SILO)United States$0.003B-1.57